Skip to main content

SMS Pharmaceuticals Ltd

NSE: SMSPHARMA BSE: 532815Pharma

SMS Pharmaceuticals Ltd is a diversified and integrated pharmaceutical company with interests in Active Pharmaceutical Ingredients (API) and Intermediates.[1]

398
52W: ₹208 — ₹448
PE 42.6 · Book ₹81.2 · +390% vs book
Market Cap₹3,724 Cr
Stock P/E42.6Price to Earnings
ROCE12.2%Return on Capital
ROE11%Return on Equity
Div. Yield0.1%Face Value ₹1

Strengths

  • +Company has been maintaining a healthy dividend payout of 24.8%

Weaknesses

  • Stock is trading at 4.88 times its book value
  • Company has a low return on equity of 7.39% over last 3 years.
  • Company might be capitalizing the interest cost

Shareholding Pattern

Promoters68.07%
FIIs0.31%
DIIs3.02%
Public28.6%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters64.67%64.67%64.67%66.27%1.666.27%68.07%1.868.07%68.07%
FIIs0.18%0.52%0.30.31%0.20.08%0.20.03%0.10.28%0.30.04%0.20.31%0.3
DIIs2.13%2.55%0.42.55%2.43%0.13.03%0.62.88%0.13.21%0.33.02%0.2
Public33.03%32.27%0.832.47%0.231.23%1.230.68%0.628.77%1.928.69%0.128.6%0.1

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales167161246164197173248196242210
Expenses139133212131165140207157194167
Operating Profit28293333323341394844
OPM %17%18%14%20%16%19%17%20%20%21%
Net Profit12121616141721182523
EPS ₹1.421.441.881.931.682.032.332.052.682.49

AI Insights

Revenue Trend

TTM revenue at ₹897Cr, up 14.6% YoY. OPM at 19%.

Debt Position

Borrowings at ₹324Cr. Debt-to-equity ratio: 0.43x. Healthy balance sheet.

Capex Cycle

CWIP at ₹50Cr (10% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 3.02% (+3.02pp change). FIIs: 0.31% (-0.36pp change). Promoters hold 68.07%.

Margin & Efficiency

ROCE improving from 12% (Mar 2014) to 12% (Mar 2025). Working capital days: 88.

Valuation

PE 42.6x with 12.2% ROCE. Price is 390% above book value of ₹81.2. Dividend yield: 0.1%.

Recent Announcements